サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1793031

転移性大腸がん治療薬の世界市場

Metastatic Colorectal Cancer Drugs

出版日
ページ情報
英文 279 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.42円
転移性大腸がん治療薬の世界市場
出版日: 2025年08月18日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 279 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

転移性大腸がん治療薬の世界市場は2030年までに38億米ドルに達する見込み

2024年に33億米ドルと推定された転移性大腸がん治療薬の世界市場は、2024～2030年の分析期間においてCAGR 2.6%で成長し、2030年には38億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである抗EGFR阻害剤は、CAGR 2.2%を記録し、分析期間終了時には18億米ドルに達すると予測されます。抗VEGF治療薬セグメントの成長率は、分析期間中CAGR 1.9%と推定されます。

米国市場は8億9,870万米ドルと推定、中国はCAGR 4.9％で成長すると予測

米国の転移性大腸がん治療薬市場は、2024年に8億9,870万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに7億3,870万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは4.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.0％と2.0％と予測されています。欧州では、ドイツがCAGR 1.4%で成長すると予測されています。

世界の転移性大腸がん治療薬市場- 主要動向と促進要因のまとめ

技術革新は転移性大腸がんの治療をどのように再構築しているか？

転移性大腸がん（mCRC）の治療状況は、科学的イノベーションとより個別化された治療アプローチの出現により、大きな変革期を迎えています。FOLFOXやFOLFIRIのような伝統的な化学療法レジメンは、依然としてmCRC治療の基幹を形成しているが、標的療法や免疫療法によって補強されたり、取って代わられたりすることが増えています。セツキシマブやパニツムマブのような上皮成長因子受容体（EGFR）阻害剤やベバシズマブのような血管内皮成長因子（VEGF）阻害剤のような特定のバイオマーカーを標的とする薬剤は、腫瘍のプロファイルに基づいて患者により適した選択肢を導入しています。ゲノムのプロファイリングとリキッドバイオプシー技術の進歩により、腫瘍医はKRAS、NRAS、BRAFなどの変異を同定できるようになり、これらは治療法の選択に重要な役割を果たしています。マイクロサテライト不安定性高値（MSI-H）またはミスマッチ修復欠損（dMMR）腫瘍の患者に対しては、ペムブロリズマブやニボルマブなどの免疫チェックポイント阻害剤が、化学療法単独では見られない持続的な奏効を示し、目覚ましい成果を示しています。さらに、二重特異性抗体や抗体薬物複合体は、より特異性の高い細胞傷害性薬剤をがん細胞に直接送達する有望な治療法として台頭してきています。精密医療が重視されるようになったことで、HER2増幅型やNTRK融合型陽性のmCRCなど、まれなサブタイプに合わせた低分子阻害剤の開発も進んでいます。さらに、複数の作用機序を含む併用レジメンが、耐性を克服し生存期間を延長するために積極的に検討されています。これらの技術革新により、転移性結腸・直腸がんの治療は、画一的なモデルから、より個別化された効果的な治療へとパラダイムシフトしつつあります。

臨床試験とバイオマーカー探索は将来のパイプラインをどのように形成するか？

転移性大腸がん治療薬の世界のパイプラインは、新規治療薬だけでなく、新たな予測・予後バイオマーカーの発見に焦点を当てた臨床研究活動の急増によって大きな影響を受けています。第I相から第III相臨床試験は、バイオマーカーによる層別化を念頭にデザインされるようになってきており、多様な遺伝子プロファイルにおける治療効果をより正確に評価できるようになってきています。研究開発者は、KRAS G12C、PI3K、METなどの新たな標的を調査しており、同時に既存の薬剤耐性を克服できる次世代阻害剤を開発しています。リキッドバイオプシーと循環腫瘍DNA（ctDNA）技術は、微小残存病変の同定、治療効果のモニタリング、再発の早期発見において、ますます大きな役割を果たしています。これらの進歩は、新たなデータに応じて修正を可能にする適応型臨床試験デザインへの移行を加速させ、有望な新薬候補の市場投入までの時間を短縮しています。また、学術機関、製薬企業、規制当局間の協力も、研究スケジュールを迅速化し、治験薬へのアクセスを拡大しています。さらに、チェックポイント阻害剤、がんワクチン、T細胞療法を含む免疫療法の組み合わせは、無増悪生存率や全生存率の改善が期待され、進行した病期で厳格に試験されています。特定の治療法に特別によく反応するサブグループを特定する試験の成功は、治療ラインの再定義と維持戦略の開発を促しています。医薬品開発企業が現実のエビデンスと国際的な臨床試験データを基に開発を続けているため、mCRCパイプラインはより多様化し、層別化され、進化する疾患の分子理解に沿ったものとなっています。

どのような市場力学が薬剤の入手しやすさと採用に影響を与えているか？

転移性大腸がん治療薬のアクセシビリティと採用は、地域によって大きく異なる規制、経済、ヘルスケアシステムのダイナミクスの複雑な相互作用の影響を受けています。高所得国では、強力な償還の枠組み、迅速な規制当局の承認、精密診断への広範なアクセスにより、先進的な治療が容易に利用できます。しかし、中低所得地域では、コストの障壁、限られたヘルスケア・インフラ、不十分なスクリーニング・プログラムによって、医薬品へのアクセスが依然として制約されています。生物学的製剤や免疫療法の高価格は、新興国市場でも引き続き大きな課題となっており、バリューベースの価格設定モデルやアウトカムベースの償還契約への注目が高まっています。VEGF阻害剤とEGFR阻害剤についてはバイオシミラーが市場に出始めており、コスト削減と生物学的製剤へのアクセス拡大の可能性があります。さらに、ヘルスケアプロバイダーや保険会社は、費用対効果に優れ、かつエビデンスに基づいた治療法を支持するクリニカルパスや治療ガイドラインを採用するようになってきており、それによって処方行動に影響を及ぼしています。患者支援団体や非政府組織も、認知度の向上、アクセスプログラムへの資金提供、政策変更の提唱において、より積極的な役割を果たしています。遠隔腫瘍学プラットフォームや分子診断ツールと統合された電子カルテなどのデジタルヘルスツールは、タイムリーな診断と個別化された治療計画に役立っています。一方、ゲノム検査へのアクセスにおける格差は依然としてボトルネックであり、多くの環境における精密医療の実際の適用を制限しています。世界の医療制度が複雑ながん医療に適応し続ける中、コスト、アクセス、臨床効果の力学は、mCRC治療薬の採用と流通を管理する意思決定プロセスにおいてますます中心的な要素となっています。

転移性大腸がん治療薬市場の成長を促進する要因とは？

転移性大腸がん治療薬市場の成長は、進化する治療技術、罹患率の上昇、プレシジョン・オンコロジーに対する世界の関心の高まりに根ざしたいくつかの要因によって牽引されています。主要な成長要因の1つは、患者数の拡大です。大腸がんは依然として世界で最も多いがんの1つであり、患者のかなりの部分が進行期または転移期で診断されるからです。バイオマーカー探索と分子診断学の進歩は、より正確な患者層別化を可能にし、ひいては臨床転帰の改善を示す標的療法や免疫療法の採用を支えています。特定の作用機序を持つ低分子化合物や生物学的製剤を含む新規薬剤のFDAやEMAの承認数が増加しており、臨床医が利用できる治療手段は急速に拡大しています。製薬会社はがん研究開発パイプラインに多額の投資を行っており、転移性結腸直腸がんはアンメット・クリニカル・ニーズと市場ポテンシャルから戦略的な焦点となっています。併用療法の統合は治療の複雑さと期間を促進し、患者一人当たりの市場価値を高めています。さらに、コンパニオン診断薬や分子プロファイリングツールへのアクセスが向上したことで、より幅広い層で精密治療の実現性が高まっています。実臨床データと市販後調査の普及は、メーカーが長期的価値を実証するのに役立ち、規制当局の承認と有利な償還決定を支えています。さらに、学術研究センターとバイオ医薬品企業との連携強化は、技術革新を加速し、臨床試験への参加を拡大しています。最後に、患者中心の取り組み、ヘルスケア適用範囲の拡大、QOL指標の重視の高まりが、mCRC治療薬市場の持続的成長にとって世界的に有利な環境を形成しています。

セグメント

薬剤クラス（抗EGFR阻害剤、抗VEGF療法、抗HER2療法、免疫チェックポイント阻害剤、その他薬剤クラス別）、流通チャネル（病院薬局、小売薬局、オンライン流通チャネル）

調査対象企業の例

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Genentech, Inc.
  • Merck & Co., Inc.
  • Merck KGaA（EMD Serono）
  • Mirati Therapeutics, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Qilu Pharmaceutical Co., Ltd.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Taiho Pharmaceutical Co., Ltd.

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP37381

Global Metastatic Colorectal Cancer Drugs Market to Reach US$3.8 Billion by 2030

The global market for Metastatic Colorectal Cancer Drugs estimated at US$3.3 Billion in the year 2024, is expected to reach US$3.8 Billion by 2030, growing at a CAGR of 2.6% over the analysis period 2024-2030. Anti-EGFR Inhibitors, one of the segments analyzed in the report, is expected to record a 2.2% CAGR and reach US$1.8 Billion by the end of the analysis period. Growth in the Anti-VEGF Therapies segment is estimated at 1.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$898.7 Million While China is Forecast to Grow at 4.9% CAGR

The Metastatic Colorectal Cancer Drugs market in the U.S. is estimated at US$898.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$738.7 Million by the year 2030 trailing a CAGR of 4.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.0% and 2.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.4% CAGR.

Global Metastatic Colorectal Cancer Drugs Market - Key Trends & Drivers Summarized

How Is Innovation Reshaping Treatment for Metastatic Colorectal Cancer?

The treatment landscape for metastatic colorectal cancer (mCRC) is undergoing a profound transformation driven by scientific innovation and the emergence of more personalized therapeutic approaches. Traditional chemotherapeutic regimens such as FOLFOX and FOLFIRI continue to form the backbone of mCRC treatment, but they are increasingly being augmented or replaced by targeted therapies and immunotherapies. Drugs targeting specific biomarkers, such as epidermal growth factor receptor (EGFR) inhibitors like cetuximab and panitumumab, and vascular endothelial growth factor (VEGF) inhibitors like bevacizumab, have introduced more tailored options for patients based on their tumor profiles. Advances in genomic profiling and liquid biopsy techniques are enabling oncologists to identify mutations such as KRAS, NRAS, and BRAF, which play a critical role in therapy selection. For patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) tumors, immune checkpoint inhibitors such as pembrolizumab and nivolumab have demonstrated remarkable outcomes, offering durable responses not seen with chemotherapy alone. Moreover, bispecific antibodies and antibody-drug conjugates are emerging as promising modalities, delivering cytotoxic agents directly to cancer cells with greater specificity. The growing emphasis on precision medicine is also leading to increased development of small-molecule inhibitors tailored to rare subtypes, including HER2-amplified or NTRK fusion-positive mCRC. Additionally, combination regimens involving multiple mechanisms of action are being actively explored to overcome resistance and extend survival. These innovations are collectively shifting the paradigm from a one-size-fits-all model to a more individualized and effective treatment landscape for metastatic colorectal cancer.

How Are Clinical Trials and Biomarker Discovery Shaping the Future Pipeline?

The global pipeline for metastatic colorectal cancer drugs is being heavily influenced by a surge in clinical research activity, focused not only on novel therapeutics but also on uncovering new predictive and prognostic biomarkers. Phase I to Phase III clinical trials are increasingly designed with biomarker stratification in mind, enabling a more precise evaluation of treatment efficacy across diverse genetic profiles. Researchers are investigating new targets such as KRAS G12C, PI3K, and MET, while simultaneously developing next-generation inhibitors that can overcome existing drug resistance. Liquid biopsy and circulating tumor DNA (ctDNA) technologies are playing a growing role in identifying minimal residual disease, monitoring therapeutic response, and enabling early detection of relapse. These advances are accelerating the move toward adaptive clinical trial designs, which allow for modifications in response to emerging data, thereby reducing time-to-market for promising drug candidates. Collaboration between academic institutions, pharmaceutical companies, and regulatory agencies is also expediting research timelines and expanding access to investigational drugs. Furthermore, immunotherapy combinations involving checkpoint inhibitors, cancer vaccines, and T-cell therapies are being rigorously tested in advanced stages of the disease, with the hope of improving progression-free and overall survival rates. The success of trials in identifying subgroups that respond exceptionally well to certain therapies is prompting a redefinition of treatment lines and the development of maintenance strategies. As drug developers continue to build on real-world evidence and global clinical trial data, the mCRC pipeline is becoming more diversified, stratified, and aligned with the evolving molecular understanding of the disease.

What Market Dynamics Are Influencing Drug Accessibility and Adoption?

The accessibility and adoption of metastatic colorectal cancer drugs are influenced by a complex interplay of regulatory, economic, and healthcare system dynamics that vary significantly by region. In high-income countries, advanced treatments are more readily available due to strong reimbursement frameworks, faster regulatory approvals, and widespread access to precision diagnostics. However, in middle- and low-income regions, drug access remains constrained by cost barriers, limited healthcare infrastructure, and inadequate screening programs. The high cost of biologics and immunotherapies continues to pose a significant challenge, even in developed markets, leading to increased focus on value-based pricing models and outcomes-based reimbursement agreements. Biosimilars are beginning to enter the market for VEGF and EGFR inhibitors, potentially reducing costs and expanding access to biologic therapies. Furthermore, healthcare providers and insurers are increasingly adopting clinical pathways and treatment guidelines that favor cost-effective yet evidence-based therapies, thereby influencing prescribing behavior. Patient advocacy groups and non-governmental organizations are also playing a more active role in promoting awareness, funding access programs, and advocating for policy changes. Digital health tools, such as tele-oncology platforms and electronic health records integrated with molecular diagnostic tools, are aiding in timely diagnosis and personalized treatment planning. Meanwhile, disparities in access to genomic testing remain a bottleneck, limiting the real-world application of precision medicine in many settings. As global health systems continue to adapt to the complexities of oncology care, the dynamics of cost, access, and clinical efficacy are increasingly central to the decision-making processes that govern mCRC drug adoption and distribution.

What Factors Are Driving Growth in the Metastatic Colorectal Cancer Drugs Market?

The growth in the metastatic colorectal cancer drugs market is driven by several factors rooted in evolving therapeutic technologies, rising incidence rates, and increasing global focus on precision oncology. One of the primary growth drivers is the expanding patient population, as colorectal cancer remains among the most common cancers worldwide and a significant portion of patients are diagnosed at an advanced or metastatic stage. Advances in biomarker discovery and molecular diagnostics are enabling more accurate patient stratification, which in turn supports the adoption of targeted therapies and immunotherapies that are showing improved clinical outcomes. The increasing number of FDA and EMA approvals for novel agents, including small molecules and biologics with specific mechanisms of action, is rapidly expanding the therapeutic arsenal available to clinicians. Pharmaceutical companies are heavily investing in oncology R&D pipelines, with metastatic colorectal cancer representing a strategic focus due to unmet clinical needs and market potential. The integration of combination therapies is driving treatment complexity and duration, thereby increasing the market value per patient. In addition, improved access to companion diagnostics and molecular profiling tools is making precision treatment more feasible across broader demographics. The proliferation of real-world data and post-marketing surveillance is helping manufacturers demonstrate long-term value, which supports regulatory acceptance and favorable reimbursement decisions. Furthermore, greater collaboration between academic research centers and biopharmaceutical firms is accelerating innovation and expanding clinical trial participation. Finally, patient-centric initiatives, expanded healthcare coverage, and a growing emphasis on quality of life metrics are shaping a more favorable environment for the sustained growth of the mCRC drugs market globally.

SCOPE OF STUDY:

The report analyzes the Metastatic Colorectal Cancer Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors, Other Drug Classes); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Genentech, Inc.
  • Merck & Co., Inc.
  • Merck KGaA (EMD Serono)
  • Mirati Therapeutics, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Qilu Pharmaceutical Co., Ltd.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Taiho Pharmaceutical Co., Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Metastatic Colorectal Cancer Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Prevalence of Late-Stage Diagnoses Throws the Spotlight on Demand for Targeted mCRC Therapies
    • Advancements in Biomarker-Driven Treatment Protocols Drive Adoption of Precision Oncology Drugs
    • Expansion of Immunotherapy Indications Spurs Growth in Checkpoint Inhibitor-Based Combinations
    • Rising Uptake of Liquid Biopsy Accelerates Demand for Molecularly Targeted mCRC Therapies
    • Personalized Medicine Trends Strengthen the Business Case for Genomic-Guided Treatment Approaches
    • Development of Novel Antibody-Drug Conjugates (ADCs) Propels Innovation in Late-Line mCRC Treatment
    • High Treatment Costs and Reimbursement Challenges Create Barriers but Also Opportunities for Value-Based Drug Models
    • Growing Emphasis on Quality of Life and Extended Survival Generates Demand for Less Toxic Therapeutic Options
    • Combination Therapies with Chemotherapy and Biologics Expand the Addressable Market for Drug Developers
    • Emergence of Small Molecule Inhibitors Disrupts Traditional Biologic-Only Treatment Paradigms
    • Rising Access to Oncology Care in Emerging Markets Expands Commercial Opportunities for Global mCRC Drug Makers
    • Evolving Companion Diagnostics Ecosystem Drives Precision in Drug Selection and Treatment Outcomes for mCRC
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Metastatic Colorectal Cancer Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Metastatic Colorectal Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Anti-EGFR Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Anti-EGFR Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Anti-EGFR Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Anti-VEGF Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Anti-VEGF Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Anti-VEGF Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Anti-HER2 Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Anti-HER2 Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Anti-HER2 Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Immune Checkpoint Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Immune Checkpoint Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Immune Checkpoint Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Metastatic Colorectal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • JAPAN
    • Metastatic Colorectal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CHINA
    • Metastatic Colorectal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: China 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • EUROPE
    • Metastatic Colorectal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Metastatic Colorectal Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • FRANCE
    • Metastatic Colorectal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: France 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • GERMANY
    • Metastatic Colorectal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Metastatic Colorectal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Metastatic Colorectal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Metastatic Colorectal Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Metastatic Colorectal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • INDIA
    • Metastatic Colorectal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: India 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Metastatic Colorectal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Metastatic Colorectal Cancer Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Metastatic Colorectal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Metastatic Colorectal Cancer Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AFRICA
    • Metastatic Colorectal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030

IV. COMPETITION